vimarsana.com

Page 3 - Cholangitis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Global Primary Biliary Cholangitis Therapeutics Market to be Driven by increasing awareness campaigns in the Forecast Period of 2021-2026

Cell Stress Mechanisms in Liver Disease Identified

Cell Stress Mechanisms in Liver Disease Identified by Colleen Fleiss on  April 1, 2021 at 7:11 AM A new prognostic factor for primary sclerosing cholangitis (PSC) from liver biopsies has been identified by researchers. This is so-called cellular ER stress. Primary sclerosing cholangitis (PSC) is a rare, chronic, inflammatory disease of the bile ducts and is difficult to treat, since its causes have not yet been adequately researched. PSC is a rare disease with a poor prognosis and can lead to cirrhosis of the liver or bile duct cancer. It affects 0.01% of the population but, even though it is rare, PSC is responsible for more than 10% of all liver transplants, making it the third most common indication on liver transplant waiting lists in Europe.

DGAP-News: Immunic, Inc Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis

DGAP-News: Immun . DGAP-News: Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis vom 18.02.2021, 12:30 Uhr Bild: pixabay.com DGAP-News: Immunic, Inc. / Key word(s): Study results Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis 18.02.2021 / 12:30 The issuer is solely responsible for the content of this announcement. Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis - Statistically Significant Decrease in Serum Alkaline Phosphatase (ALP) Levels in the Per-Protocol Population After 24-Week IMU-838 Treatment, as Compared to Baseline -

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.